January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Vivek Subbiah: I’ll be speaking at the Keystone Precision Oncology Meeting
Jan 13, 2025, 16:53

Vivek Subbiah: I’ll be speaking at the Keystone Precision Oncology Meeting

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), reshared a post on X by David B. Solit, Director of Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center, adding:

“Delighted to announce that I’ll be speaking at the Keystone Precision Oncology Meeting, one of the top events in precision medicine tomorrow at Keystone Symposia.

Wow.

The speaker lineup is absolutely stellar- kudos to the organizers for rounding up an all-star MVP speaker team:

  • David B. Solit
  • Christine Lovly
  • Lillian Siu
  • AACR President Patricia M. LoRusso
  • Carl Yates Perry
  • Rizwana Mia
  • Pam Sharma
  • Marta Luksza
  • Christina Curtis
  • Benjamin D. Greenbaum
  • Vivek Subbiah
  • Eli Van Allen

 Don’t miss out.

  • When: January 12-15, 2025 
  • Where: Beaver Run Conference Center, Breckenridge, CO, USA.”

Quoting David B. Solit’s post:

“Accepting abstracts for the Precision Oncology Keystone meeting January 12-25, 2025 with my co-organizers John D. Carpten and Chanita Hughes-Halbert. Great lineup of speakers including Elaine Mardis, Frank McCormick, Christine Lovly, Vivek Subbiah, Patricia LoRusso, Rick Kittles, Clayton Yates, Rizwana Mia, Padmanee Sharma, Marta Luksza, Alona Sosinsky, Christina Curtis, Colin Weekes, David Craig, Benjamin Greenbaum, and Eliezer Van Allen.

The deadline for financial aid is October 15th.

Link for the program.”

Vivek Subbiah

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.

More posts featuring Vivek Subbiah.